EA3571 for Obesity and MASH Treatment

EA3571 is a novel oral enteropeptidase/trypsin dual inhibitor with first-in-class potential. EA3571 inhibits the digestion of ingested protein and fat in the small intestine. It also secretes multiple endogenous hormones by mimicking the effects of protein restriction. In preclinical, EA3571 reduced only fat mass without affecting lean mass in an obese model, resulting in significant weight loss in obese model. Furthermore, EA3571 in mice fast food diet-induced MASH model confirmed its efficacy not only on liver inflammation, fibrosis and steatosis but also on body weight and dyslipidemia.

A Phase 1 study involving healthy Japanese and Caucasian subjects demonstrated that EA3571 was safe and well-tolerated in both the SAD and MAD cohorts. Gastrointestinal adverse events such as nausea, vomiting, and diarrhea, as observed with GLP1R agonists, were not observed in this study. Additionally, changes in mechanism-related biomarkers were observed.

We look for a partner for development and commercialization.